![]() | |
Clinical data | |
---|---|
Trade names | Lupkynis |
Other names | VCS, ISA247, Luveniq |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ECHA InfoCard | 100.357.472 |
Chemical and physical data | |
Formula | C63H111N11O12 |
Molar mass | 1214.646 g·mol−1 |
3D model (JSmol) | |
| |
|
Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis.[2][4] It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.[5]
It was approved for medical use in the United States in January 2021,[6][7][8] and in the European Union in September 2022.[3] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[9]
Drug Approval Package: Lupkynis
was invoked but never defined (see the help page).